Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes.
Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, Voss NC, Mahadevan NR, Mizuno K, Puca L, Idahor O, Ku SY, Bakht MK, Borah AA, Herbert ZT, Tolstorukov MY, Barbie DA, Rickman DS, Brown M, Beltran H. Venkadakrishnan VB, et al. Among authors: puca l. Res Sq [Preprint]. 2024 Mar 4:rs.3.rs-3935288. doi: 10.21203/rs.3.rs-3935288/v1. Res Sq. 2024. PMID: 38405800 Free PMC article. Preprint.
Emerging Variants of Castration-Resistant Prostate Cancer.
Vlachostergios PJ, Puca L, Beltran H. Vlachostergios PJ, et al. Among authors: puca l. Curr Oncol Rep. 2017 May;19(5):32. doi: 10.1007/s11912-017-0593-6. Curr Oncol Rep. 2017. PMID: 28361223 Free PMC article. Review.
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X, Hwang I, Bagadion AM, Sboner A, Elemento O, Paik J, Yu J, Barbieri CE, Dephoure N, Beltran H, Rickman DS. Berger A, et al. Among authors: puca l. J Clin Invest. 2019 Jul 1;129(9):3924-3940. doi: 10.1172/JCI127961. J Clin Invest. 2019. PMID: 31260412 Free PMC article.
The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.
Van Emmenis L, Ku SY, Gayvert K, Branch JR, Brady NJ, Basu S, Russell M, Cyrta J, Vosoughi A, Sailer V, Alnajar H, Dardenne E, Koumis E, Puca L, Robinson BD, Feldkamp MD, Winkis A, Majewski N, Rupnow B, Gottardis MM, Elemento O, Rubin MA, Beltran H, Rickman DS. Van Emmenis L, et al. Among authors: puca l. Cancer Res Commun. 2023 Aug 3;3(8):1447-1459. doi: 10.1158/2767-9764.CRC-22-0491. eCollection 2023 Aug. Cancer Res Commun. 2023. PMID: 37546702 Free PMC article.
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T, Cheung C, Yuen KS, Gao D, Chen Y, Eilers M, Mosquera JM, Robinson BD, Elemento O, Rubin MA, Demichelis F, Rickman DS. Dardenne E, et al. Among authors: puca l. Cancer Cell. 2016 Oct 10;30(4):563-577. doi: 10.1016/j.ccell.2016.09.005. Cancer Cell. 2016. PMID: 27728805 Free PMC article.
Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors.
Mosquera MJ, Kim S, Bareja R, Fang Z, Cai S, Pan H, Asad M, Martin ML, Sigouros M, Rowdo FM, Ackermann S, Capuano J, Bernheim J, Cheung C, Doane A, Brady N, Singh R, Rickman DS, Prabhu V, Allen JE, Puca L, Coskun AF, Rubin MA, Beltran H, Mosquera JM, Elemento O, Singh A. Mosquera MJ, et al. Among authors: puca l. Adv Mater. 2022 Jan;34(2):e2100096. doi: 10.1002/adma.202100096. Epub 2021 Nov 14. Adv Mater. 2022. PMID: 34676924 Free PMC article.
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
Conteduca V, Ku SY, Puca L, Slade M, Fernandez L, Hess J, Bareja R, Vlachostergios PJ, Sigouros M, Mosquera JM, Sboner A, Nanus DM, Elemento O, Dittamore R, Tagawa ST, Beltran H. Conteduca V, et al. Among authors: puca l. Mol Cancer Ther. 2020 May;19(5):1157-1164. doi: 10.1158/1535-7163.MCT-19-0926. Epub 2020 Mar 3. Mol Cancer Ther. 2020. PMID: 32127465 Free PMC article.
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.
Che M, Chaturvedi A, Munro SA, Pitzen SP, Ling A, Zhang W, Mentzer J, Ku SY, Puca L, Zhu Y, Bergman AM, Severson TM, Forster C, Liu Y, Hildebrand J, Daniel M, Wang TY, Selth LA, Hickey T, Zoubeidi A, Gleave M, Bareja R, Sboner A, Tilley W, Carroll JS, Tan W, Kohli M, Yang R, Hsieh AC, Murugan P, Zwart W, Beltran H, Huang RS, Dehm SM. Che M, et al. Among authors: puca l. Nat Commun. 2021 Nov 4;12(1):6377. doi: 10.1038/s41467-021-26612-1. Nat Commun. 2021. PMID: 34737261 Free PMC article.
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L, Pan H, Motanagh S, Hess J, Donoghue AJ, Sboner A, Wang Y, Dittamore R, Rickman D, Nanus DM, Tagawa ST, Elemento O, Mosquera JM, Saunders L, Beltran H. Puca L, et al. Sci Transl Med. 2019 Mar 20;11(484):eaav0891. doi: 10.1126/scitranslmed.aav0891. Sci Transl Med. 2019. PMID: 30894499 Free PMC article. Clinical Trial.
35 results